Navigation Links
Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
Date:3/2/2009

to systemic administration in blocking the asthmatic activities of IL-4 and IL-13 and has the potential to provide a breakthrough treatment for a patient population with few options."

AeroTrial is a late-stage clinical study using a dry powder formulation and follows positive clinical data from two Phase IIa studies in which Aerovant demonstrated significant benefit in asthmatics who were experimentally challenged with inhaled allergen (The Lancet 2007, 370: 1422-31). The dry powder formulation that will be used in AeroTrial was well tolerated in a recently completed Phase I study in asthmatics. By using a medication based on a protein occurring naturally in the body, AeroTrial seeks a non-steroidal solution to getting control of asthma. For more information, visit www.aerotrial.com.

Aerovant is a recombinant human IL-4 variant that is a potent inhibitor of the alpha subunit of the IL-4 receptor (IL-4R alpha), a shared component of both the IL-4 and IL-13 receptor complexes. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004.

Aerovance Inc. is a Berkeley, California-based biopharmaceutical company focused on the development and commercialization of first-in-class therapies for the treatment of respiratory and inflammatory diseases. For more information, visit www.aerovance.com.

Contact: Andreas Marathovouniotis or David Schull

Russo Partners

212-845-4235 or 212-845-4271

andreas.marathis@russopart
'/>"/>

SOURCE Aerovance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Show Aerovances Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
(Date:7/30/2015)... Inc. (NYSE: RMD ) today announced results for ... quarter was $453.1 million, a 9 percent increase compared ... percent increase on a constant currency basis).  Net income ... 30, 2014.  Diluted earnings per share for the quarter ... 2014.  The results for the quarter ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... , , ... to unveil TPNstation,s development plans and product specifications,for a new and ... i.v. Room of the Future vision to be,showcased at Las Vegas, ... forward to see the reaction from our customers to the,TPNstation,s blueprints ...
... , WALTHAM, Mass., Nov. 30 Decision Resources, ... on pharmaceutical and healthcare issues, forecasts that the hepatitis C ... over the 2008 - 2013 study period, reaching $327 million ... government spending on healthcare and increased use of more-expensive therapies ...
Cached Medicine Technology:Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 3Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and warm-season turfgrasses, ... of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, ... of this new type of sod, Super-Sod is giving away red Adirondack chairs with ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator for ... applicator in the United States as an upgrade to the CoolSmooth applicator cleared by ... required a 2 hour treatment time. The new CoolSmooth Pro reduces the treatment ...
(Date:7/31/2015)... Mountain View, CA (PRWEB) , ... July 31, 2015 , ... ... hand for the athletes, judges, media, and VIPs at the 2015 Vans US Open ... best-tasting organic coconut water that can claim “no added sugar” on the market, is ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... see if they could reach a consensus on the steps that need to be ... the group reached 90 percent consensus on a series of steps that each surgeon ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... - Contract Extended One Year -LEXINGTON, Mass., Jan. ... MedAssets Supply Chain Systems has extended its contract ... 2010. This continues a successful history between ... in 2002.The contract covers IL,s portfolio of critical ...
... Medimetriks Pharmaceuticals announced today that the Company ... (Nasdaq: PRGO ), a leading manufacturer in ... Authorized Distributor of generic versions of Medimetriks, branded products ... to receive a percentage of Perrigo,s Net Sales on ...
... HEIGHTS, N.J., Jan. 26 Authentidate Holding Corp. ... of secure Health Information Exchange and workflow management ... from representatives of Parascript, LLC and Parascript Management, ... Agreement and Plan of Merger it entered into ...
... standards snag company awardIRVINE, Calif., Jan. 26 ... in phytochemical reference standards and contract research, announced ... natural products and alternative health care magazine, selected ... Scientific Achievement Award recipients for its achievement in ...
... 26 Trintech Group Plc (Nasdaq: TTPA ... transaction risk management, and compliance solutions, today announced that ... meet on January 27 in Mountain View, California as ... share common experiences, discuss the latest market trends and ...
... announced,that it has launched the International College ... surgical teams from around the world.,The launch was announced ... San Francisco. , "We have ... we began our program in 2002," says Kirk Wilson, ...
Cached Medicine News:Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 2Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 3Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 2Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 3Health News:Authentidate Announces Termination of Merger Agreement With Parascript, LLC 2Health News:Authentidate Announces Termination of Merger Agreement With Parascript, LLC 3Health News:ChromaDex Awarded Nutrition Business Journal Scientific Achievement 2Health News:KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times 2Health News:KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times 3Health News:Saint Joseph's Launches International College of Robotic Surgery 2
... is designed to help you achieve one ... brachytherapy procedure. All needles are engineered for ... surfaces for smooth entry and exit. A ... assures an ideal match with procedural needs ...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
ACMI™ Double-J Closed Tip Ureteral Stents feature patented dual durometer thermosensitive Tecoflex® construction for physician ease of placement and patient comfort....
Medicine Products: